• Home
  • Site Map
  • Contact Us
  • Graphics Version
  • Printer Version

Amarin

Main Navigation

  • ABOUT US
    • COMPANY PROFILE
    • STRATEGY
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
    • CONTACT US
  • THERAPEUTIC FOCUS
    • CARDIOVASCULAR
    • CNS
      • Huntington's Disease
      • Myasthenia Gravis
      • Parkinson's Disease
      • Epilepsy
  • PRODUCTS
    • PIPELINE
    • AMR101 for Hypertriglyceridemia
    • AMR101 for HD
    • EN101
    • SUBLINGUAL APOMORPHINE
    • NASAL LORAZEPAM
    • AMR103
  • SCIENCE & TECHNOLOGY
    • INTRODUCTION
      • Lipophilic Platform
      • Targeted Lipid Transport Technology Platform
      • Cholinergic Platform
  • PARTNERING
    • PARTNERING
    • BUSINESS DEVELOPMENT
    • STRATEGIC ALLIANCES
  • INVESTOR RELATIONS
    • OVERVIEW
    • STOCK INFORMATION
    • CORPORATE GOVERNANCE
      • AUDIT COMMITTEE
      • REMUNERATION COMMITTEE
      • LEAD INDEPENDENT DIRECTOR
      • CODE OF ETHICS
      • MEMORANDUM AND ARTICLES OF ASSOCIATION
    • PRESENTATIONS
    • PRESS RELEASES
    • EVENTS
    • INVESTOR FAQ
    • REQUEST INVESTOR KIT
    • FINANCIAL REPORTS
    • SEC FILINGS
    • AGM 2008
    • EGM 2008
    • AGM 2007
    • ANALYST COVERAGE
    • EMAIL ALERTS
    • REQUEST INFORMATION

INVESTOR RELATIONS

  • OVERVIEW
  • STOCK INFORMATION
  • CORPORATE GOVERNANCE
  • PRESENTATIONS
  • PRESS RELEASES
  • EVENTS
  • INVESTOR FAQ
  • REQUEST INVESTOR KIT
  • FINANCIAL REPORTS
  • SEC FILINGS
  • AGM 2008
  • EGM 2008
  • AGM 2007
  • ANALYST COVERAGE
  • EMAIL ALERTS
  • REQUEST INFORMATION

Mailing List

Mailing List
Unsubscribe »

INVESTOR RELATIONS

AGM 2008

 

Type Description File Size
 PDF

Notice of AGM 2008

 
 PDF Annual Report for year ending 31 December 2007  
 PDF Proposed Changes to Memorandum and Articles of Association  

 

 

Registered in England and Wales No. 2353920 - Registered Office: 110 Cannon Street, London, EC4N 6AR

  • Disclaimer
  • Privacy Policy

© 2009 Amarin

Link opens in new windowWeb Design by Webtrade.ie